Bull’s Eye Report: Pharmacyclics (PCYC)

Pharmacyclics (PCYC) is our top pick today as an outperformer in the biotech space. More 

Bull’s Eye Report: Pharmacyclics (PCYC)

Biotech is a hot industry that's extremely volatile right now. Get on the right side of that volatility with Pharmacyclics (PCYC). More 

Bull’s Eye Report: United Therapeutics Group (UTHR)

United Therapeutics (UTHR) should move back up to recent highs around $63, and today presents a great opportunity to get in. More 

Make a Straightforward Play in Biotech

The iShares Nasdaq Biotechology Index Fund is a great way to get into biotechs ... just not now. It's due for a buyers' exhaustion break, so wait and keep watch. More 

Bull’s Eye Report: Regeneron Pharmaceuticals (REGN)

Looking for a non-correlated asset to beat the market in a potential downturn? Look no further than biotech stock Regeneron Pharmaceuticals (REGN). More 

Bull’s Eye Report: Regeneron Pharmaceuticals (REGN)

REGN gained 208.65% on the year in 2012, and while normally this would indicate a parabolic run, the short-term prospects for a trade still look pretty good. More 

My Brilliant Biotech Move for 2012

An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple. More